Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00647777 | Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg | PHASE1 | COMPLETED | 32 | — | — | Jun 1, 2003 | Jul 1, 2003 | Apr 24, 2024 | 1 | United States |
| NCT00648921 | Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg | PHASE1 | COMPLETED | 30 | — | — | Jun 1, 2003 | Jul 1, 2003 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Olanzapine Tablets 5 mg |
| 2 | ACTIVE_COMPARATOR | Zyprexa® Tablets 5 mg |
| Name | Type | Description |
|---|---|---|
| Olanzapine Tablets 5 mg | DRUG | 5mg, single dose fed |
| Zyprexa® Tablets 5 mg | DRUG | 5mg, single dose fed |
Inclusion Criteria: 1\. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration....